The use of defibrotide in blood and marrow transplantation was discussed. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr.Spyridis, Dr.Aggelinas

A paper in BV entitled "Prediction of cardiovascular disease among  hematopoietic cell transplantation survivors" was presented. Presenter: Prof. Spyridonidis Participants: Dr.Liga, Dr Spyridis, Dr. Aggelinas

Based on a case of our unit we discussed "Outcomes of patients who  developed subsequent solid cancer after hematopoietic cell  transplantation" Presenter:Prof.Spyridonidis Participants:Dr.Liga, Dr.Spyridis, Dr.Aggelinas

A paper published in Blood Advances and entitled "How ibrutinib, a  B-cell malignancy drug, became an FDA-approved second-line therapy for  steroid-resistant chronic GVHD" was presented. Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas

An excellent review/focus from R Storb. His fazit, " Therefore, faced with the choice of an HLA-identical sibling marrow  graft or even an alternative donor graft vs immunosuppression, many  patients should be counseled in favor of marrow transplantation as  first-line therapy."   Presenter:Prof. Spyridonidis Participants:Dr. Liga, Dr.Spyridis, Dr Aggelinas

A recent study published in Blood advances "Evaluation of induction  chemotherapies after hypomethylating agent failure in myelodysplastic  syndromes and acute myeloid leukemia" was presented. Induction led to response in 41% and 32%, survival of 10.8 and 6 months,  and transplant in 40% and 42% of responders in MDS...

We discussed the emerging data of the importance of asparaginase in the  treatment of ALL. We discussed the potential toxicities and how we can  manage them. The time point of application plays after cheotherpay is of  major importance. Monitoring for pancreatitis and bleeding should be  done routinely. Presenter: Prof....

We discussed the current literature regarding the role of allo HCT in  the era of BV and PD1 blockade for HD. Patients with cHL who are ineligible for auto-HCT or relapse after  auto-HCT have historically had a poor prognosis with a median survival  of 2 years or...

A patient with JAkavi resistant LF who was referred to our unit was  presented and discussed. We also presented the current How I treat paper  form Blood. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

The Oncopedia 2018 update on CLL treatment algorithm has presetend and  discussed. Presenter: Prof. Spyridondis Partricpants: Dr Liga, Dr Spyridis, Dr Aggelinas  

Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Aggelinas   Main studies in newly diagnosed MM (NDMM) presented in 23. Congress, European Hematology Association (EHA), Stockholm, Sweden.   ALCYONE NDMM, >65y, auto non-eligible Daratumumab (D) plus Bortezomib-Melphalan-Prednison (VMP) vs VMP more CR, PFS nr vs 20,4 Mo, no problems with addtion of Daratumumab  GIMEMA  Phase-3, NDMM  Bortezomib, Thalidomid-Dexamethason (VTD) vs TD, pre...

Presenter: Dr Liga Participants:Prof. Spyridonidis, Prof. Marangos, Dr Spyridis, Dr Aggelinas

The update of WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES was presented. Presenter: Prof:Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal of the educational session is to understand the role of DPB1 mismatched in allo Tx. We discussed their level of expression and  their alloreactivity as is scored in the TCE algorithm. We also discussed a new proposed methodology which defines the DPB1 alloreactivity...

Scope: To update the current treatment management of CLL in the elderly. Presenter: Dr Spyridis Participants: Prof. Spyridonidis, Dr Liga, Dr Aggelinas.

Based on a case we discussed the current treatment guidelines for essential thrombocythemia. Dr Spyridis presented the current How I treat Blood paper. Presenter: Dr Spyridis Participants: Prof: Spyridonidis, Dr Liga, Dr Aggelinas

We discussed a recent review of the Treatment Options for Carbapenem- Resistant Gram-Negative Infections. We additionally reviewed our current policy in treating these infections and implemented a new policy. Presenter: Prof. Marangos Participants: Prof. Spyridonidis, Dr Spyridis, Dr Liga, Dr Aggelinas.

We discussed novel insights regarding the pathophysiology of CRS after CART therapy published in Nature Medicine. Activation of macrophages plays a major role.